Not yet recruiting
A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07865910· Phase 2/3· Shanghai Henlius Biotech· Source
Contact: Li ya Wan
Not yet recruiting
A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC
NCT07720193· Phase 3· Nanjing Leads Biolabs Co.,Ltd· Source
Contact: xiangyu Ma
Not yet recruiting
Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
NCT07821606· Phase 3· Hansoh BioMedical R&D Company· Source
Contact: Ding Ma, PhD
Not yet recruiting
A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
NCT07784101· Phase 3· Beijing InnoCare Pharma Tech Co., Ltd.· Source
Contact: Yingyu Nan
Recruiting
Safety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07871110· Phase 2· TransThera Sciences (Nanjing), Inc.· Source
Contact: Li
Not yet recruiting
Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)
NCT07712588· Phase 2/3· Dizal Pharmaceuticals· Source
Contact: Liu
Recruiting
DEC003M in Prostate Cancer
NCT07657806· Phase 1· Hangzhou DAC Biotechnology Co., Ltd.· Source
Contact: Junyong Dai, MD (Doctor of Medicine)
Recruiting
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
NCT07492680· Phase 2· Bristol-Myers Squibb· Source
Contact: Haifeng Yang, Site 0185
Recruiting
A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer
NCT07462143· Phase 2/3· RemeGen Co., Ltd.· Source
Contact: Hongfang Li
Not yet recruiting
A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal Cancer
NCT07543848· Phase 2· Chongqing University Cancer Hospital· Source
Contact: Bo Yi, MD
Recruiting
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
NCT07409428· Phase 3· Hutchmed· Source
Contact: Yao Liu
Recruiting
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497· Phase 3· Bristol-Myers Squibb· Source
Contact: Wei Zhou, Site 0308
Recruiting
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849· Phase 3· Incyte Corporation· Source
Recruiting
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
NCT07227415· Phase 1/2· Pfizer· Source
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566· Phase 3· Pfizer· Source
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357· Phase 2/3· Bristol-Myers Squibb· Source
Contact: Jianghong Wang, Site 0499
Recruiting
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380· Phase 3· Eli Lilly and Company· Source
Contact: Fang Yuan (principal investigator)
Recruiting
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
NCT07222800· Phase 3· Pfizer· Source
Recruiting
A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
NCT07179679· Phase 1· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Contact: Yao Liu, Doctor
Recruiting
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
NCT07283835· Phase 2· Lepu Biopharma Co., Ltd.· Source
Contact: Fang Yuan
Recruiting
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
NCT07217301· Phase 3· Takeda· Source
Contact: Huiwen Ma
Recruiting
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
NCT06899126· Phase 3· Daiichi Sankyo· Source
Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280· Phase 3· Pfizer· Source
Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853· Phase 3· Pfizer· Source
Recruiting
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT07111520· Phase 1/2· BioNTech SE· Source
Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
NCT07082686· Phase 2· Beijing InnoCare Pharma Tech Co., Ltd.· Source
Contact: Qiying Li
Recruiting
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
NCT07070232· Phase 1/2· BioNTech SE· Source
Recruiting
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
NCT07094113· Phase 1· Amgen· Source
Recruiting
A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer
NCT07059221· Phase 1/2· Suzhou Suncadia Biopharmaceuticals Co., Ltd.· Source
Contact: Ying Wang (principal investigator)
Recruiting
Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy
NCT07823049· Phase 3· Evopoint Biosciences Inc.· Source
Contact: Yingjie zhao
Recruiting
ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
NCT07327034· Phase 2· Abbisko Therapeutics Co, Ltd· Source
Contact: Dewei Li
Recruiting
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
NCT06907043· Phase 1/2· Eikon Therapeutics· Source
Contact: Yongsheng Li-PI
Recruiting
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310· Phase 3· Mirati Therapeutics Inc.· Source
Contact: Dan Yang, Site 0490
Recruiting
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
NCT06801834· Phase 3· Gilead Sciences· Source
Recruiting
Ondansetron Orodispersible Film for Vomiting Prevention in Pediatric Radiotherapy
NCT07217600· Phase 4· Chongqing University Cancer Hospital· Source
Contact: Yue Xie
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
NCT06797297· Phase 2· Innovent Biologics (Suzhou) Co. Ltd.· Source
Recruiting
A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
NCT07673029· Phase 3· GeneQuantum Healthcare (Suzhou) Co., Ltd.· Source
Contact: Xianjun Tang
Recruiting
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
NCT06564324· Phase 3· Nuvation Bio Inc.· Source
Contact: Huiwen Ma
Active, not recruiting
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06711900· Phase 3· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Source
Active, not recruiting
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
NCT06551324· Phase 3· Pfizer· Source
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386· Phase 3· Bristol-Myers Squibb· Source
Contact: Chunmei Wang, Site 0238
Active, not recruiting
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441· Phase 3· Gilead Sciences· Source
Active, not recruiting
Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation Pneumonitis
NCT06700421· Phase 2· Wei Zhou· Source
Recruiting
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
NCT06427941· Phase 1/2· BeOne Medicines· Source
Contact: Study Director
Not yet recruiting
Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer
NCT06475599· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Dong Wang, Bachelor
Active, not recruiting
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
NCT06419621· Phase 3· Biotheus Inc.· Source
Active, not recruiting
A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06448312· Phase 3· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Source
Recruiting
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
NCT06203210· Phase 3· Daiichi Sankyo· Source
Contact: Principal Investigator
Showing 50 of 117.